ClinConnect ClinConnect Logo
Search / Trial NCT02127580

Balloon Expandable Transcatheter Aortic Valve Implantation Without Predilation of the Aortic Valve

Launched by INSTITUT FÜR PHARMAKOLOGIE UND PRÄVENTIVE MEDIZIN · Apr 29, 2014

Trial Information

Current as of April 25, 2025

Completed

Keywords

Thv Bav Pre Dilation Aortic Valve Stenosis

ClinConnect Summary

Prior to the deployment of transcatheter heart valves (THV), balloon aortic valvuloplasty (BAV) is usually performed under rapid right ventricular pacing (burst \>180 bpm) with the induction of a functional cardiac arrest for up to 30 seconds. Aortic valve predilation is aiming at facilitating the crossing of the aortic annulus, accurate valve positioning and does also provide information on the anatomy of the valve complex. However, BAV has been shown to have a number of potentially detrimental effects, such as:

* Functional cardiac arrest induced by rapid pacing leads to transient corona...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Patients with an indication for TAVI as to the Edwards THV IFU
  • Eligible for TABI with AND without BAV
  • Signed informed consent
  • Exclusion Criteria:
  • Logistic EuroSCORE I \>50%
  • Mitral or tricuspid valvular insufficiency (\> grade II)
  • Previous aortic valve replacement
  • Uncontrolled atrial fibrillation
  • Left ventricular or atrial thrombus by echocardiography
  • Recent cerebrovascular event (within the last 3 months)
  • High probability of non-adherence to the follow-up requirements (due to social, psychological or medical reasons)

Trial Officials

Holger Schröfel, MD

Principal Investigator

Clinic for Cardiac Surgery Karlsruhe

Justus Strauch, Prof.

Principal Investigator

Klinik für Herz- und Thoraxchirurgie

About Institut Für Pharmakologie Und Präventive Medizin

The Institut für Pharmakologie und Präventive Medizin is a leading research institution dedicated to advancing the fields of pharmacology and preventive medicine. With a strong focus on innovative clinical trials, the institute aims to develop and evaluate novel therapeutic strategies to improve patient outcomes and enhance public health. By fostering collaboration among multidisciplinary teams of researchers, clinicians, and industry partners, the institute is committed to translating scientific discoveries into practical applications that address unmet medical needs. Its rigorous research framework and commitment to ethical standards ensure the integrity and reliability of its clinical trials.

Locations

Augsburg, , Germany

Karlsruhe, Baden Württemberg, Germany

Bochum, Nordrhein Westfalen, Germany

Bad Neustadt An Der Saale, , Germany

Bad Rothenfelde, , Germany

Essen, , Germany

Köln, , Germany

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials